Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.58 |
| ▸ | MTOR | P42345 | 14/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.56 |
| ▸ | PRKDC | P78527 | 5/20 | 0.56 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.56 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.56 |
| ▸ | LTK | P29376 | 1/20 | 0.56 |
| ▸ | CDK7 | P50613 | 1/20 | 0.56 |
| ▸ | NEK2 | P51955 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31439321 | 1.00 | PIK3CA (0.58) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL993134 | 0.88 | PIK3CA (0.74) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL31439293 | 0.86 | MTOR (0.49) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL368346 | 0.86 | PIK3CA (0.44) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL368347 | 0.86 | PIK3CA (0.44) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL9905243 | 0.85 | PIK3CA (0.62) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL15133603 | 0.84 | PIK3CA (0.63) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL9905035 | 0.83 | MTOR (0.81) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL9905318 | 0.83 | PIK3CA (0.62) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL15388223 | 0.83 | PIK3CA (0.71) | PIK3CAMTORPIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062046-B2 | Substituted imidazoquinoline derivatives as kinase inhibitors | Piramal Enterprises Limited (IN) | 2015-06-23 | — | — | US | disclosed |
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | PIRAMAL ENTERPRISES LIMITED` (IN) | 2013-11-21 | — | — | US | disclosed |
| EP-2648733-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | Piramal Enterprises Limited (IN) | 2013-10-16 | — | — | EP | disclosed |
| EP-2593450-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-22 | — | — | EP | disclosed |
| CN-103108873-A | Substituted imidazoquinoline derivatives as kinase inhibitors | PIRAMAL LIFE SCIENCES LTD | 2013-05-15 | — | — | CN | disclosed |
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-09 | — | — | US | disclosed |
| WO-2012077031-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
| CN-102399218-A | Triheterocyclic compounds and their use as PI3K inhibitors | HUTCHISON MEDIPHARMA LTD | 2012-04-04 | — | — | CN | disclosed |
| WO-2012007926-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK4, MAP3K1 | PIK3CA 72/4885MTOR 102/4885PIK3CD 115/4885 |
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | FLT4, CDK4, CDK2 | PIK3CA 154/4885MTOR 220/4885PIK3CD 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.